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of the rise of a biotechnology subsector during
the Human Genome Project, 1990 to 2004
Ilse R Wiechers1,3*, Noah C Perin1 and Robert Cook-Deegan1,2Abstract
Background: Development of the commercial genomics sector within the biotechnology industry relied heavily on
the scientific commons, public funding, and technology transfer between academic and industrial research. This
study tracks financial and intellectual property data on genomics firms from 1990 through 2004, thus following
these firms as they emerged in the era of the Human Genome Project and through the 2000 to 2001 market
bubble.
Methods: A database was created based on an early survey of genomics firms, which was expanded using three
web-based biotechnology services, scientific journals, and biotechnology trade and technical publications. Financial
data for publicly traded firms was collected through the use of four databases specializing in firm financials. Patent
searches were conducted using firm names in the US Patent and Trademark Office website search engine and the
DNA Patent Database.
Results: A biotechnology subsector of genomics firms emerged in parallel to the publicly funded Human Genome
Project. Trends among top firms show that hiring, capital improvement, and research and development
expenditures continued to grow after a 2000 to 2001 bubble. The majority of firms are small businesses with great
diversity in type of research and development, products, and services provided. Over half the public firms holding
patents have the majority of their intellectual property portfolio in DNA-based patents.
Conclusions: These data allow estimates of investment, research and development expenditures, and jobs that
paralleled the rise of genomics as a sector within biotechnology between 1990 and 2004.Background
A cluster of companies that employed genomic technol-
ogy emerged in parallel to the publicly funded Human
Genome Project between 1990 and 2004 [1,2]. The business
plans, technologies, size and financial health of these firms
differed widely, but they shared a common reliance on
methods and technologies associated with the then-new
field of genomics: DNA sequencing, DNA manipulation on
the chromosome or whole-genome scale, and bioinfor-
matics. These firms drew heavily on the scientific com-
mons, public funding, availability of startup capital,* Correspondence: ilse.wiechers@yale.edu
1Center for Public Genomics, Institute for Genome Sciences & Policy, Duke
University, Box 90141, Durham, NC 27708, USA
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reproduction in any medium, provided the orand two-way technology transfer between academic
and industrial research.
As originally conceived, the Human Genome Project
was a public works project - to construct maps and derive a
reference sequence for the human genome and other ge-
nomes. Maps and reference sequences were primarily con-
ceived as scientific tools, but they have obvious commercial
implications. New genomics firms began to form in the
early 1990s, five years after the Human Genome Project
was first conceived in 1985. The firms built on three
decades of molecular biology and human genetics re-
search to develop a commercial genomics sector within
biotechnology. The information tools - maps, sequences,
and algorithms - generally (with some exceptions) resided
in the public domain through scientific publications in
open literature and public databases. The Human Genome
Project also relied upon automated DNA sequencing andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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research and development (R&D). Academic research
institutions were the first market for instruments, re-
agents, software and other projects of many genomics
firms. Knowledge and technology moved from academe to
industry and also from industry into academic research. In
the late 1980s, instrumentation for DNA sequencing,
mapping, and polymerase chain reaction became a growth
sector. The promise of applications in developing pharma-
ceutical products, diagnostics, and biologics, as well as agri-
cultural uses, led to adoption of genomics by established
firms and creation of new firms that extensively used the
nascent technologies.
Most of the private genomics R&D investment began
in 1992 and 1993 [3], initially among United States (US)
firms or foreign firms investing in US genomics R&D.
The first wave of such genomics firms formed around
the idea of mapping or sequencing the human genome,
finding genes associated with known genetic characters,
or shifted their focus from other pursuits to those ends.
Public and nonprofit funding for biomedical R&D grew
steadily through the 1980s; privately funded R&D, however,
grew even faster, surpassing total public and nonprofit
funding by the early 1990s [4]. In genomics, the rise of
private R&D was even more sudden and pronounced.
From very little investment in private genomics at the
beginning of the 1990s as the Human Genome Project
began, a survey of genomics research funding for the
World Health Organization found that private firm expen-
ditures were almost twice the public and nonprofit funding
for genomics R&D by 2000 [5].
One notable historical feature of genomics is that it
grew out of publicly funded science at a time when patent
rights were being expanded and strengthened through a
combination of changes in legislation, court decisions, and
patent office policies. The Human Genome Project was
conceived just a few short years after the 1980 passage of
the Bayh-Dole Act (Public Law 96–517), which clarified
grantees’ and contractors’ rights to seek patents on federally
funded research results [6]. Academic institutions expanded
their patenting following Bayh-Dole [7], and genomics is
one of the areas where the effect was pronounced. The
number of DNA patents - that is, US patents that refer to a
DNA-specific term in their claims - surged dramatically
during the 1990s (see Figure 1).
Technology transfer greatly stimulated the nascent
genomics sector; many genomic technologies relating to
DNA sequencing and genetic mapping spent a period of
gestation in academic R&D. Yet many of the instruments
(for example, automated DNA sequencing machines), and
some of the most important techniques (such as polymer-
ase chain reaction), were developed in private firms through
industrial R&D. The market for genomic technologies
is thus a complex hybrid of public and private R&Dlaboratories, with many technologies starting in private
R&D with the goal of development, at least in part, for
the academic research market. This history gives genomics
firms a distinctive business model; one that involves both
direct funding through government grants and contracts
and indirect funding through sales of products and ser-
vices to federally funded or nonprofit laboratories. This
is by no means unique, but the degree to which private
instrumentation and biotechnology companies devel-
oped was remarkable and happened in a short period,
less than a decade.
What is genomics?
The definition of ‘genomics’ derives from Tom Roderick,
as first cited in print by McKusick and Ruddle in the in-
augural editorial for the new journal Genomics in 1987
[9]. At that time, genomics distinguished large-scale map-
ping and sequencing efforts from molecular studies of one
or a few genes [10]. The term genomics gained popularity
and came to describe a rapidly growing field of molecular
biology, applying to large-scale, rapid DNA analysis, and in-
tensive use of instruments and new technologies. Lederberg
and McCray noted that by 2001, ‘genomics’ had acquired a
broader meaning, referring to any study that involved the
analysis of DNA sequence and even to the study of how
genes affect biological mechanism and phenotype [11]. In
current parlance, it generally means studies that generate
enormous rates of data flow and require extensive compu-
tation centered on DNA structure and function, particularly
DNA sequencing or metrics of DNA variation.
This work aims to describe commercial genomics as it
emerged in parallel to the publicly funded Human Genome
Project. We present here descriptive financial and intellec-
tual property data on genomics firms between 1990 and
2004. This allows us to track the sector through the market
blip in March 2000, when Prime Minister Tony Blair and
President Bill Clinton made a public announcement about
DNA sequence patents that led to a dramatic but transient
drop in stock valuations, as well as the bubble in late 2000
and into early 2001. Our data provide a glimpse of some
underlying trends in the financial inputs and scientific
outputs of genomics as it emerged as a subsector within
biotechnology (see Major Findings).
Major findings
 Genomics firms engaged in more than 20 distinct
types of business activity.
 Hiring, capital improvement, and R&D expenditures
continued to grow despite a tremendous loss of
market capitalization in 2000 through to 2001.
 The ability to identify patents referencing
DNA-specific terms allows a measure of ‘genomics
intensity’ of R&D. The genomics firms identified,
Figure 1 Number of items loaded into DNA Patent Database, by year through 2013. [8] Creative Commons ‘free use with attribution’
license, with the attribution to Genomics Policy Resource.
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genomics.
 Genomics firms grew to employ at least 28,000
people by 2004.
 Most genomics firms were small businesses.
Methods
This description of an emerging sector was enabled by
two data sources: a database of firms and R&D expendi-
tures initiated at Stanford University and continued at
Duke University through 2004 (when the company data-
base was discontinued for reasons described below);
and the ability to identify patents making claims that
specify terms distinctive to DNA or RNA. The data also
construct a window through which to view technology
transfer, patenting, and academic-industrial-government
interactions, using genomics as an important subset of
biotechnology.
Identifying genomics firms
The definition of what is or is not a genomics firm is
somewhat amorphous. Similar to how the term biotech-
nology refers to the practice of a subset of pharmaceutical
firms employing molecular biological methods, genomics
is an approach, not an industrial sector. One unifying
feature among the many companies that became known
as genomics firms and were included in our database
was that all or a substantial fraction of their business
plans hinged on use of large datasets on several or many
genes, emerging DNA technologies of sequencing, novel
methods of DNA detection, or interpretation of informa-
tion based on DNA sequence or structure. This is not
restricted to human DNA, but also includes microbes,
plants, and other organisms. However, it became increas-
ingly difficult to determine exactly what portion of a firm’s
business was related to genomics as the technologies rami-
fied into many disparate lines of life sciences and industrialapplication. R&D allocations by firms on our list range
from complete dedication to genomics to only a small, but
meaningful, fraction of R&D funds attributed to genomics.
With this in mind, our dataset of genomics firms is a best
effort estimation of the genomics sector as it emerged, but
should not be viewed as an exact valuation of how much
genomics R&D was taking place in the commercial sector.
We used the following criteria to include firms in our
analysis: analysis of DNA structure a core business; ‘genom-
ics’ listed on website, annual report, or in news stories as
part of the business plan; and firm listed as ‘genomics’ by
stock analysts or trade press (subject to correction if deter-
mined not to meet one of the above criteria). We accepted
the definitions of those reporting the figures (including
the trade press characterization of private firms). When
reporting on firms and funding programs, we visited
websites or read publicly available data sources. We
excluded firms solely or primarily focused on protein,
rather than DNA structure, or those that identified
themselves as primarily ‘proteomics’ or some other ‘-omics’
field other than genomics. These distinctions were not en-
tirely consistent, details about the technologies used were
not always explicit, and the amount of information publicly
available varied widely. Many firm descriptions made it
difficult to make judgments. The rule of thumb was to
exclude firms unless they (or others writing about them)
explicitly referred to genomics, or when the nature of
their business seemed similar to other firms already on
the list. In cases of doubt, firms were contacted for
clarification, and excluded or included according to the
taxonomy noted below.
General firm information
The database of genomics firms began from two sources:
a December 1993 survey of early genomics firms done
by one of the authors (RCD; contract report available at
the National Reference Center for Bioethics Literature,
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2000 Genomics Review [12]. Our list was then expanded
using several principal sources: three web-based biotech-
nology services (BioSpace.com, Recombinant Capital, and
GenomeWeb.com), scientific journals, and biotechnology
trade and technical publications. A few firms were also
identified by membership in the Biotechnology Industry
Organization or brought to our attention by scientists,
stock analysts, or other firms on our list. The database
of genomics firms was maintained through 2004, the
year after the Human Genome Project formally ended
with publication of the human reference sequence in
April 2003 [13].
To assemble contact information on firms, we visited the
websites for each firm (except the few lacking websites),
and made phone calls to clarify points of uncertainty. Our
monitoring was greatly expedited by use of the following
sources: news about genomics firms in BioSpace.com’s daily
‘Breaking News’ service; twice daily GenomeWeb Daily
News Bulletins; Genomics Today, a news service of the
Pharmaceutical Research and Manufacturers Association;
and reading scientific and trade journals.
We made efforts to gather the following information
for each firm in the database: current and former names;
contact information such as address, phone, fax, website,
and executive officers; year founded; firm taxonomy
(as described below); and total number of issued US
patents and DNA-based patents (see description of search
methods below).
Each firm was designated as being either public, pri-
vate, acquired, subsidiary, nonprofit, dissolved, or lost to
follow-up. Firms that had undergone merger were classi-
fied under the acquired category. A firm was designated
as dissolved only when direct evidence of dissolution of
the business was uncovered (for example, press report,
direct contact with former management or staff ). All
other firms that we could not locate (by web search, or
former phone or email contact) but for which we did
not have direct evidence of dissolution were considered
lost to follow-up.
The database of genomics firms was discontinued in
2004. This was partly a choice to end the study with
completion of the Human Genome Project, partly because
the data-collection effort was substantial and our research
project ended, and partly because the term ‘genomics’
became difficult to justify as a coherent, distinctive category
as genomic technologies became ubiquitous in the life
sciences and in industrial applications. The problem of
definitional wobble is apparent even in government funding
programs devoted to genomics, although reasonable
estimates were possible for nonprofit and government
funding streams through 2008 [14].
One of the limitations of our survey is the relative dearth
of trade press or other sources for collecting informationabout firms outside North America and Western Europe.
We acknowledge that our coverage is not uniform and that
we may have missed a significant number of international
companies. Firms in India, China, other parts of Asia, Latin
America, and Eastern Europe are very likely under-
represented. This bias applies to publicly traded firms,
but is true a fortiori for privately held firms, which can
be very difficult to identify and monitor.
Business taxonomy
A genomics taxonomy emerged from reviewing descriptions
of R&D carried out by the firms that were described by
themselves, on websites or in annual reports, or by others in
the trade press and news websites as ‘genomics firms.’ The
categories emerged from a bootstrapping process of classify-
ing companies, comparing results of classification among the
research team, adding terms to accommodate new categories
up to a point of ‘saturation’ when few reclassifications were
needed; inter-rater reliability was established. Categories in
the taxonomy are not mutually exclusive; each firm can be
classified under multiple headings.
Financial data
For publicly traded genomics firms, we gathered the fol-
lowing additional annual financial data: total operating ex-
penses, R&D expenses, number of employees, plant and
equipment values, total revenues, net income, and market
capitalization. Market capitalization was either gathered
directly from financial data sources or was calculated by
taking the product of the adjusted closing value of the stock
on the day of fiscal year end and the reported number of
outstanding shares in the annual financial reports.
Financial data for publicly traded US and international
firms were collected primarily through the use of four data-
bases specializing in firm financials: Mergent Online - U.S
Company Data [15], Compustat North America [16],
Thomson Research - Worldscope [17], and OneSource -
Business Browser [18]. The source of these databases’
information is US Securities and Exchange Commission
filings, press releases, and analyst reports. In some cases,
when companies were not listed in one of these databases,
we gathered data directly from firm annual reports. Despite
accessing multiple data sources, there remain several firms
for which we were unable to locate all financial data points.
(Data tables are included in supplemental materials,
see Additional file 1) Our aggregate data are thus only
a rough proxy for collective activity in private commercial
genomics, not comprehensive and fine-grained analyses of
particular firms or technologies.
Patent searches
To obtain the count of total issued US patents, we
conducted searches using the US Patent and Trademark
Office website search engine [19]. Searches were done
Table 2 Genomics firms taxonomy
Category Description
AGRIVET Agriculture and veterinary genomics
DATABSE Database creation, subscription, or licensing
DNASEQN DNA sequencing
DNATEST DNA testing service, clinical or diagnostic screening
DRUGDEV Drug, biologic, and vaccine development
GENEFNL Gene function and functional genomics;
characterization of genes and their products
GENEMAP Gene mapping; linkage, association studies;
SNP discovery, use and analysis
GENEPOP Genetic epidemiology; population studies
GENETFR Gene transfer and gene therapy; vectors for gene therapy
GENEXPR Gene expression analysis; microarray analysis;
analysis of siRNAs and other regulation element
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the assignee on patents. Efforts were made to incorpor-
ate the patents of acquired and subsidiary firms into the
total count of patents for parent firms. We also searched
for common misspellings and typos for firm names,
when appropriate. Total issued US patent counts were
current through 7 February 2006, covering two years be-
yond the period for which we report company financial
data. This two-year period approximates the time of
traditional total pendency for patents at the US Patent
and Trademark Office [20].
The many distinctive terms for DNA and RNA allow
DNA patents to be identified with a relatively high degree
of specificity and sensitivity, providing an analytical tool
to study genomic innovation. To obtain the count of DNA-
based patents, we conducted searches for issued US patents
in the DNA Patent Database (DPD) [21]. Established in
1994, the DPD contains patents (and, since 1999, patent
applications) with one or more claims explicitly referring to
DNA or RNA or terms of art specific to DNA (for example,
‘plasmid’ or ‘nucleotide’), mapping patents to the field of
genomics. This patent collection goes well beyond just gene
patents (usually referring to DNA molecules encoding
proteins) to include methods, instruments, and software.
The search algorithm is available online [22]. The individual
terms used in the DPD were tested individually for specifi-
city and sensitivity in 1997 and the algorithm modified and
re-tested in 2003. Our searches were performed using the
2003 algorithm and utilized techniques similar to those
described above for total issued US patents. DPD patent
counts cited here are up to date through 11 January 2006,
also covering two years beyond the period for which we
report company financial data. Comparing DNA patents to
total patents yields a ratio of genomics to other patenting
activity, a rough indicator of ‘genomics intensity.’
Results
The final database contained information on 470 genomics
firms from 25 different countries, 1990 through 2004. The
majority of publicly traded and privately held genomics
firms in our database were in the US; 75% and 62%, re-
spectively. Canada, Germany, France, United Kingdom,
and Japan rounded out the top six countries (see Table 1).Table 1 Top countries with genomics firms
Country Public Private Nonprofit Total
United States 65 130 1 196
Canada 6 17 1 24
Germany 6 15 0 21
France 0 10 0 10
United Kingdom 3 6 0 9
Japan 0 5 0 5The firms by type in 2004 were: private (211, 45%),
public (88, 19%), acquired (90, 19%), subsidiary (27, 6%),
dissolved (23, 5%), nonprofit (2, 0.4%), and lost to follow-
up (29, 6%). Thus 30% of firms had either dissolved, been
acquired, or had become subsidiaries of another larger firm
since 1990. The number of publicly traded firms was 88 in
2004, reaching this peak in 2002 and subsequently sta-
bilizing. Consolidation occurred after 2001, as established
pharmaceutical and biotechnology firms sought to fill gaps
in their research programs or intellectual property holdings.
In addition, smaller firms merged. Consolidation in part
explained the leveling effect on the overall numbers of
publicly traded firms.
Review of the genomics taxonomy revealed the R&D
being completed by firms in our database included almost
20 different classifications of research, ranging from agri-
cultural genomics to DNA sequencing to forensics to drug
development (see Table 2). The most common category
for both public and private firms was ‘drug, biologic and
vaccine development;’ accounting for 55% of public firms
(for example, Millennium Pharmaceuticals) and 33% of
privately held firms (for example, AGY Therapeutics).
Approximately one quarter of public firms were in the
business of providing ‘instruments for DNA analysis’
(for example, Affymetrix). Another 20% of public firmsIDNTFCN DNA forensics, DNA identification service
INFRMTX Bioinformatics for DNA analysis; data mining
INSTRMT Instruments for DNA analysis
LEGLSVC Legal services; privacy protection
PHRMGEN Pharmacogenetics or pharmacogenomics
STANDRD Setting standards, testing service benchmarks
SUPPLYR Genomics reagents supplier; microarray manufacturer;
service provider
TRSTFND Trust fund or genomics capital source
SYNBIOL Synthetic biology
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array manufacturer; service provider’ (e.g. Invitrogen) or
‘DNA testing service, clinical or diagnostic screening
service, test kit manufacturing’ (e.g. Gen-Probe). Almost 30
percent of private firms were involved in ‘bioinformatics for
DNA analysis; data mining’ (for example, DNAStar) and
over 20% conducted ‘gene expression analysis; microarray
analysis; or analysis of siRNAs and other regulation
element’ (for example, Ipsogen).
Financial data on publicly traded genomics firms
Total global market capitalization for the publicly traded
firms dropped 52% from the 2000 peak value of over $84
billion to the 2004 value of $40 billion (see Figure 2). The
top 15 genomics firms, based on market capitalization
value in 2004, represented over 70% of the total genomics
sector’s value, over $28 billion. These top 15 firms spent a
combined $2 billion in R&D, generated $4.3 billion in
annual revenues, and had just under $2 billion in plant,
property, and equipment in 2004 (see Figure 3). Analysis
of the top 15 firms demonstrated broad growth trends,
indicating that R&D and capital improvement continued
to increase both before and after the 1998 to 2001 bubble,
despite the 2000 peak and following decline in market
capitalization. These trends in the top 15 firms paralleled
the consistent growth in total revenues and R&D expendi-
tures for all publicly traded firms.
The majority of genomics firms were not profitable by
the end of 2004. Even those considered successful and
ranking in the top 15 by market capitalization had an
aggregate net income in 2004 of negative $1.2 billion.
However, beginning in 2003, net income for the sector
had begun to trend upwards, that is, there was an aggregate
reduction in losses (see Figure 4). Through 2004, total reve-
nues for the genomics sector continued to climb, and in
2004 generated approximately $6.3 billion in revenues, with
a combined net income of negative $2.5 billion.Figure 2 Aggregate market capitalization of all genomics firms.Employment trends
Employment trends in the top 15 genomics firms by
market capitalization showed that hiring increased both
before and after the bubble, reaching its highest point
during the study period in 2004 at over 17,000 people
(see Figure 5). The trend of the sector as a whole was
similar, though there is evidence of a decrease between
2001and 2002, which may partly be explained by data
drop out occurring after 2002. Some firms dropped out
due to acquisition or dissolution during this time period,
but others with missing data were still functioning and
reporting financial data during those years. Employment
for the sector as a whole was at its highest point during
the study period in 2004, with almost 28,000 employees
among firms reporting employment data.
Based on the US Small Business Administration Size
Standards, matched to the North American Industry
Classification System (NAICS) (using size standards for
NAICS code 541711 for ‘Research and Development in
Biotechnology’), the overwhelming majority (83%) of
genomics firms in 2004 were classified as small businesses
(employing fewer than 500 people) [23]. In fact, almost one
third of genomics firms employed fewer than 100 people.
Intellectual property outputs
Another measure of output for genomics firms and a
potential proxy for productivity is number of patents
issued. There were 5,859 US patents owned by active and
independent genomics firms in our database. Eighty-nine
percent of public firms held patents, with the top 10 firms
(by US patent count) holding nearly 60% of the total US
patents. There were 3,683 DNA-based US patents owned
by active and independent genomics firms. The top 10
firms (by DNA patent count) held 64% of all DNA patents.
Among those firms, the percentage of their intellectual
property portfolio attributed to DNA patents ranged from
44% to 93%, giving an indication of ‘genomics intensity’.
Figure 3 Financial trends of top 15 public genomics firms. Top 15 genomics firms by market capitalization are: Applera, Millennium
Pharmaceuticals, Invitrogen, OSI Pharmaceuticals, Gen-Probe, Affymetrix, Protein Design Labs, Human Genome Sciences, ZymoGenetics, Abgenix,
Incyte, Digene, Exelixis Pharmaceuticals, Lexicon Genetics, and Rigel Pharmaceuticals. PPE, plant, property and equipment; R&D Exp, research and
development expenditures; Total Exp, total expenditures.
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at large, not just the top 10 firms. Although not all firms
held patents, DNA-based patents comprised over half of
the patent portfolio among 53% of publicly traded firms
that had patents.
The financial, employment, and intellectual property
data from the publicly traded genomics firms are available
in Additional file 1.
Discussion
The emergence of a genomics sector of biotechnology was
captured from 1990 through 2004, near the beginning of its
emergence as the Human Genome Project began, to a year
after the human reference sequence was successfully
produced. The ability to track DNA-specific patents and an
ongoing database of firms maintained by a sequence ofFigure 4 Aggregate net income and total revenue for all genomics firstudents at Stanford and Duke universities enabled tracking
at the firm level. The count of firms, and their employment
and R&D expenditures, and patent outputs may be of inter-
est to those studying the emergence of the genomics sector,
or those who study quantitative aspects of innovation and
the emergence of new technologies.
Our definition of a genomics firm includes some firms
that did not base their products and services on quintes-
sential genomic technologies (such as high-throughput
sequencing or genome-wide analysis) or did not focus
on human DNA. Digene, for example, focused on human
papillomavirus diagnostics before it was acquired by
QIAGEN (after the period of our study), and Myriad fo-
cused on BRCA genetic testing (of just two genes, not many)
for most of the period in our dataset. Some firms were
established before the term genomics became broadly usedms.
Figure 5 Employment trends. Top 15 genomics firms by market capitalization are: Applera, Millennuim Pharmaceuticals, Invitrogen, OSI
Pharmaceuticals, Gen-Probe, Affymetrix, Protein Design Labs, Human Genome Sciences, ZymoGenetics, Abgenix, Incyte, Digene, Exelixis
Pharmaceuticals, Lexicon Genetics, and Rigel Pharmaceuticals.
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taxonomy categories, presented themselves as genomic in
part, or whose R&D included technologies captured by
patents in the DPD. Thus, it is important to note that some
firms in our database are not genomic in the narrower sense
in which it is often used, and not all are human or medically
focused; our data should be interpreted accordingly.
The taxonomy of activities carried out in genomics
firms captures the breadth of economic sectors and the mix
of products and services enabled by genomic technologies,
and categorization of firms gives a rough sense of how
many firms engaged in those activities. This breadth of
products, services, and business models must expand even
further among today’s firms in the era of next-generation
sequencing. The challenges of big data require creative
and unique approaches to not only the science but also
its funding [24].
One feature that emerges from the data is the extraordin-
ary growth of market capitalization value of genomics firms
for the better part of a decade until a blip in March 2000.
The valuations generally recovered and continued to grow
until after the June 2000 announcement of a draft human
genomic sequence. In the later part of 2000, however, a bub-
ble burst in both genomics and information technology
stocks, leading to a five-fold decrement in valuation of the
top 15 firms. One interesting finding from our data is that
these firms nevertheless continued to increase their R&D
expenditures in 2000 and subsequent years, despite the
dramatic drop in overall firm valuation. This suggests
these firms remained focused on R&D-intensive business
strategies, with exit, sale, or profitability dependent on
pursuing successful research pathways to products andservices, making R&D expenditure important to sustain
even in an adverse financial climate. A ‘continue to research
through the storm’ strategy appears to have been pursued
by most firms.
The aggregate statistics reported here are best interpreted
in light of case studies of technologies or in studies of
application areas. The picture that emerges by combining
aggregate statistics and individual case studies is richer than
either method alone. For example, there are numerous
genomics firms that show the intricate mutualism between
academic and industrial R&D. DNA sequencing was devel-
oped in nonprofit research institutions and the prototype
instrument for automated sequencing was developed at the
California Institute of Technology, but refinement and
development of the instrument drew on engineering
and manufacturing expertise in the startup firm Applied
Biosystems [25]. Polymerase chain reaction was discovered
at Cetus in 1983, but found immediate and widespread use
in scientific laboratories, and eventually yielded over $2
billion in revenues before the initial patents began to expire
[26]. These are just two of many examples of industrial-
academic technological interactions that underlie the data
captured by R&D expenditures, market capitalization,
patenting, and employment figures reported here.
Conclusions
These data allow estimates of investment, R&D expend-
iture, and employment that paralleled the rise of genomics
as a sector within biotechnology between 1990 and 2004.
Financial trends show hiring, capital improvement, and
R&D expenditure continued to grow after the 2000 to
2001 market bubble. There was a great diversity in the
Wiechers et al. Genome Medicine 2013, 5:83 Page 9 of 9
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were small businesses with a majority of their intellectual
property portfolio in DNA-based patents.
Additional file
Additional file 1: Microsoft Excel file containing all of the financial,
employment, and intellectual property data from the publicly
traded firms in our database.
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